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Background: Development of cigarettes that reduce exposure to harmful smoke constituents is a
suggested tobacco harm reduction strategy, but robust methods for measurement of change are required.
We investigated whether changes in biomarkers of exposure (BoE), effective dose (BoED) and
biological effect (BoBE) could be detected after switching from conventional cigarettes to a
reduced-toxicant-prototype cigarette (RTP).
Methods: Regular smokers of 6–8 mg ISO tar yield cigarettes were recruited in Hamburg, Germany, and
supplied with a conventional 7 mg ISO tar yield cigarette for 2 weeks then switched to the same cigarette
with a different tipping paper (control) or the RTP for 6 months. Subjects smoked mostly at home and
attended ﬁve residential clinic visits where urine and blood samples were collected for analysis.
Primary endpoints were changes in speciﬁc biomarker levels compared with non-smoker background
levels. Changes in daily cigarette consumption were also investigated.
Results: BoE levels in controls generally increased over the study period, whereas most BoE and all BoED
signiﬁcantly declined in RTP smokers. Most BoBE data were similar across groups and/or too variable
within individuals to detect changes. Increased daily cigarette consumption was affected by supply of
free cigarettes, perceived shorter smoking time per cigarette than usual brands, and perceived reduced
harm.
Conclusions: Despite increased cigarette consumption, reductions in BoE and BoED were detectable.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background
The health risks associated with cigarette smoking are corre-
lated with duration of smoking and amount of daily consumption,and cessation reduces an individual’s relative risks of tobacco
related disease (International Agency for Research on Cancer,
2007; Doll et al., 1994). Thus, tobacco-related health risks are
assumed to be due to repeated and sustained exposure to a rangestitute of
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health effects of tobacco use is a clear public-health priority and
has led to a series of regulatory and educational initiatives to per-
suade people not to smoke (World Health Organization, 2011).
Despite these efforts, smoking rates in adult populations world-
wide remain at 15–25%. Although numbers are declining slowly
in many countries (World Health Organization, 2011), the World
Health Organization (WHO) has forecast that there will be around
1.5 billion tobacco smokers worldwide in 2050 (World Health
Organization, 2002). Current scientiﬁc study and public-policy
debate, therefore, are concerned with whether public-health gains
could arise from reducing exposure to toxicants in people who con-
tinue to use tobacco through the development of new tobacco and
nicotine products.
In the 2001 Institute of Medicine (IoM) report, Clearing the
Smoke: the scientiﬁc basis for tobacco harm reduction (Stratton
et al., 2001), the development of potential reduced-exposure prod-
ucts (PREPs) was suggested as a possible way to achieve tobacco
harm reduction. PREPs were deﬁned as products that result in
substantial reductions in exposure to one or more tobacco toxi-
cants and that can reasonably be expected to reduce the risk of
developing one or more speciﬁc diseases or adverse health effects
as compared with risks conferred by use of traditional tobacco
products. The IoM Report describes the types of scientiﬁc studies
that might be useful for assessing potential risk reduction offered
by the PREPs, including clinical studies, but the optimum study
designs are still being considered (Hatsukami et al., 2009).
Various researchers have since been trying to develop a validated
framework for this research (Hatsukami et al., 2006).
The IoM noted the need to have initiatives related to PREPS
overseen by regulators. In the USA, the Food and Drug
Administration (FDA) was mandated by law to begin regulating
tobacco products in 2009. The legislation includes the possibility
of classifying new tobacco products as modiﬁed-risk tobacco
products (MRTPs) with allowable public claims of reduced risk or
exposure to toxicants as compared with traditional tobacco prod-
ucts. The FDA has set out draft guidance (Modiﬁed Risk Tobacco
Products Applications (Draft Guidance for Industry), 2012) on the
science needed to assess MRTPs, which is based partly on further
ﬁndings from the IoM (Committee on Scientiﬁc Standards for
Studies on Modiﬁed Risk Tobacco Products, 2011), but the opti-
mum methods for determining products’ potential to reduce
tobacco-related harm remain under development.
Tobacco smoke contains a large number of toxicant species.
Whether or not conventional cigarettes can be modiﬁed sufﬁ-
ciently to be classiﬁed as MRTPs remains unclear. Standardised
machine tests, followed by various analytical methods, can collect
and measure the levels of these constituents in tobacco smoke
under laboratory conditions (Rickert et al., 1986). Nevertheless,
cigarettes with relatively low ISO machine-measured tar yields
are generally not associated with commensurately reduced health
risks, partly because of compensatory smoking behaviour (11–13).
Hence, beside in vitro and possibly in vivo data, assessment of
MRTPs requires generating clinical data to determine whether
machine-measured reductions in toxic emissions translate to
reductions in human toxicant uptake and concomitant reduction
of health risks in relation to comparator traditional tobacco
products.
It is not entirely clear which toxicants are the most relevant to
the development of smoking-associated diseases, whether there is
a dose–response relationship between these toxicants and disease
or how toxicants may interact in various disease pathways (Fowles
and Dybing, 2003). Considerable research is being conducted, par-
ticularly with computational toxicology, to reﬁne understanding of
priority toxicants (Cunningham et al., 2011). Regulators and inter-
ested public health authorities are considering whether reductionsin levels of speciﬁc cigarette smoke toxicants might yield
public-health beneﬁts. The WHO’s Study Group on Tobacco
Product Regulation has recommended the measurement of 18 tox-
icants in cigarette smoke and suggested that regulators consider
setting progressively lower limits for nine of these (Burns et al.,
2008). The FDA’s Tobacco Products Scientiﬁc Advisory Committee
has identiﬁed 93 harmful and potentially harmful constituents
present in tobacco and tobacco smoke (FDA, 2012). The FDA now
requires US tobacco product manufacturers to measure and dis-
close levels in their products of 20 of these 93 constituents, and
has noted that it might in the future propose product standards
that include limits on smoke toxicants (FDA, 2012).
The metabolic half-lives of many tobacco-smoke toxicants are
short and changes in biomarkers of exposure (BoE) therefore, can
be assessed in studies of only a few weeks’ duration. We previously
reported a 6-week clinical study, in which smokers switched after
2 weeks from conventional cigarettes to another conventional
cigarette or to a reduced-toxicant-prototype cigarette (RTP)
Shepperd et al., 2013a. The RTP had signiﬁcantly reduced
machine-measured yields of speciﬁc smoke toxicants. In the
4 weeks after switching, exposure to toxicants assessed by mea-
surement of urinary BoE was also reduced. Generally, reductions
in BoE reﬂected the machine-measured reductions of toxicants in
smoke, and for some toxicants machine-measured and BoE levels
reached reductions of more than 70% compared with the conven-
tional cigarette. Sensorially, however, the RTPs were generally less
acceptable to smokers than were the conventional cigarettes.
Hatsukami et al. (2006) concluded that no existing biomarkers
in smokers were predictive of smoking-related disease. In the
absence of such biomarkers, these authors concluded that the best
way to evaluate PREPs (and presumably MRTPs) would be to assess
reductions in exposure, whilst noting the distinctions between
exposure reduction, risk reduction and harm reduction. Thus, a log-
ical approach to assess relations between exposure and risk or
harm is to measure biological effects. Biomarkers of biological
effect (BoBE) indicate the body’s response to exposure to toxicants
and indicate early sub-clinical changes that might contribute to
subsequent development of disease. We hypothesised that if
reductions in exposure to toxicants are maintained over the longer
term, BoBE levels will also be reduced by a detectable degree. We
therefore developed a new RTP that aimed to reduce levels of
speciﬁc toxicants whilst maintaining tar and nicotine yields and
an acceptable sensory performance and performed this 6-month
study to investigate whether the new RTP would alter both expo-
sure and response to toxicants through measurement of potential
BoE and BoBE. In addition to measurement of these biomarkers,
endpoints included cigarette consumption and sensory impres-
sions of the products. Longitudinal studies of tobacco consumption
raise methodological and ethical issues, including accuracy of
self-reporting consumption, changes in consumption because of
study participation and the maintenance of smoking that may lead
to an increase in lifetime risk of smoking-related diseases. For
example, in our 6-week study some subjects notably increased
the number of cigarettes smoked on the last day compared with
average daily consumption throughout the rest of the study, which
we believe was associated with their knowledge that provision of
free study product was coming to an end (Shepperd et al.,
2013a). Thus, in this study we obtained ethics committee approval,
allowed subjects the opportunity to quit at any time during the
study, and provided cessation advice throughout and after the
study.
The primary objective of this study was to assess changes in
selected BoE and BoBE within participants and within and between
smoking groups after a forced switch from a commercial control
cigarette to an RTP cigarette of equivalent International
Organization for Standardization (ISO) tar yield. Secondary
Table 1
Construction characteristics, smoke yields (ISO and HCI regimes) and % differences in yield for control and reduced-toxicant prototype cigarettes used in this study.
Control (v1 and
v2)
RTP
Target ISO tar yield (mg) 7 7
Tobacco blend composition US style MFVC – 50% washed, extracted & enzyme-treated tobacco/15% tobacco substitute sheet/35% other
tobaccos
Blend weight (mg) 598 490
Total cigarette length (mm) 83 83
Cigarette circumference (mm) 24.6 21
Tobacco rod length (mm) 56 46
Filter length (mm)/type 27/Mono CA 37/Triple
Mouth end section length
(mm)/type
– 7/Plain CA
Mid-section length (mm)/type – 10/CA + 20 mg AFR
Tobacco-end section length
(mm)/type
– 20/50 mg HAC
Cigarette paper 75 CU LIP 50 CU LIP
Ventilation type On-machine Laser ‘split tipping’ (see text)
Ventilation level (%) 33 35
Pressure drop (mmWG) 87 113
Control (v1 and v2) RTP % Yield change (RTP vs control)
ISO HCI ISO HCI ISO HCI
NFDPM (mg/cig) 7.1 26.3 6.4 17.8 10 32
Nicotine (mg/cig) 0.58 1.59 0.64 1.48 10 7
Carbon Monoxide (mg/cig) 7.4 22.7 5.4 15.7 27 31
Puffs per cigarette 7.2 8.2 7.6 9.1 – –
Tobacco-speciﬁc nitrosamines
NNK (ng/cig) 32.6 79.9 BLQ (<12.4) 28.3 >62 65
NNN (ng/cig) 69.5 171.4 9.9 25.4 86 85
NAT (ng/cig) 47.4 114.5 21.5 55.9 55 51
NAB (ng/cig) 8.9 18.2 2.4 6.5 73 64
Aromatic amines and misc nitrogenous
4-Aminobiphenyl (ng/cig) 1.4 3.1 0.7 1.6 50 48
3-Aminobiphenyl (ng/cig) 1.8 4.2 1.0 2.2 44 48
2-Aminobiphenyl (ng/cig) 8.1 15.5 4.5 8.7 44 44
o-Toluidine (ng/cig) 49.5 101.3 3.1 58.8 33 42
Acrylonitrile (lg/cig) 5.6 23.3 BDL (<0.28) 4.7 >95 80
Carbonyls
Acrolein (lg/cig) 43.6 137.0 BLQ 61.6 >94 55
Crotonaldehyde (lg/cig) 9.5 46.9 0.99 3.9 90 92
Hydrocarbons and PAH
1,3-Butadiene (lg/cig) 33.0 95.3 4.3 52.5 87 45
Pyrene (lg/cig) 41.5 88.3 37.2 70.9 10 17
Naphthalene (lg/cig) 257.6 1048.5 54.1 142.0 79 86
Fluorene (lg/cig) 141.4 269.2 161.5 238.8 14 11
Phenanthrene (lg/cig) 99.7 182.4 97.3 163.2 2 11
Included are the percent differences in yield of all smoke constituents for which we measured a validated BoE.
Key: ISO = International Organisation for Standardization; HCI = Health Canada Intense; MFCV = modiﬁed ﬂue-cured Virginia; CA = cellulose acetate ﬁlter material;
AFR = amine-functionalised resin; HAC = high activity carbon; CU = CORESTA units; LIP = low ignition propensity; mmWG = mm water gauge; NFDPM = nicotine free dry
particulate matter (‘tar’); NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N-nitrosonornicotine; NAB = N-nitrosoanabasine; NAT = N-nitrosoanatabine;
PAH = polycyclic aromatic hydrocarbons; BLQ = below quantitation limit; BDL = below detection limit.
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pants and within and between smoking groups in further BoE,
BoBE and biomarkers of effective dose (BoED), and other measures
(quality of life, smoking behaviours, physiological measures,
mouth-level exposure (MLE) and sensory perception, not all of
which are reported here) and to compare with values for
ex-smokers and never-smokers.2. Materials and methods
This study was a 6-month, single-centre, single-blind, con-
trolled, forced-switch clinical trial conducted by Momentum
Pharma Services, Hamburg, Germany, between March and
December 2012. The study was designed and conducted in accor-
dance with the ethical principles of the Declaration of Helsinki
and the International Committee on Harmonisation for GoodClinical Practice. The protocol was approved by the ethics commit-
tee of the Artzekammer, Hamburg. All subjects provided written
informed consent. The study is registered (ISRCTN81286286) and
the protocol has been published (Shepperd et al., 2013b).2.1. Products
Three types of cigarettes were manufactured speciﬁcally for this
study (Table 1), all with target ISO machine-measured tar and nico-
tine yields of 7.0 and 0.7 mg/cig, respectively. Two control cigar-
ettes were based on British American Tobacco king-size products
on sale in Germany at the time of the study, with overall length
83 mm (comprising a 56 mm tobacco rod and 27 mm ﬁlter), cir-
cumference 24.6 mm, American blend tobacco, and a plain cellu-
lose acetate ﬁlter with 33% ventilation achieved by on-machine
laser perforation. The two versions of the control product were
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tipping paper to maintain blinding after switching.
Apart from the ISO yields and overall length, the RTP differed
notably from the control products (Fig. 1). The format was
demi-slim (circumference 21 mm). This reduction in circumfer-
ence has been shown to contribute to a reduction in both
mainstream and sidestream smoke toxicant yield (Dittrich et al.,
2014). The tobacco rod was 46 mm long and contained a blend of
50% washed, extracted and enzyme-treated tobacco (Liu et al.,
2011), 15% tobacco substitute sheet (McAdam et al., 2011) and
35% other tobaccos. The ﬁlter was 37 mm long and comprised
three cellulose acetate segments: the front segment, nearest the
tobacco rod, contained 50 mg high-activity carbon (Branton et al.,
2011a), the middle segment contained 20 mg amine-
functionalised resin (Branton et al., 2011b) and the mouth-end
segment was plain cellulose acetate. Filter ventilation was 35%,
achieved with a combination of on-machine laser perforation and
a 10 mm wide zone of high-porosity paper (Dittrich et al., 2014).
2.2. Subjects
We enrolled 143 regular smokers, 61 ex-smokers and 61 never
smokers who responded to advertisements in the local press and
on the study clinic website. The advertisement did not include
any speciﬁc characteristics of the study products. Eligible subjects
were healthy adults of any ethnic origin who lived in or around
Hamburg. Full details of the inclusion and exclusion criteria are
detailed elsewhere (Shepperd et al., 2013b).
Universal inclusion criteria were weight of at least 52 kg (men)
or 45 kg (women), body-mass index in the normal range, no abnor-
mal clinical ﬁndings, willingness to refrain from consuming alcohol
and grilled, fried or barbequed food before in-clinic evaluations,
not being pregnant or breastfeeding, and using reliable contracep-
tion or being postmenopausal.
To be eligible for the study, smokers had to be aged 23–55 years
(i.e. minimum legal age for smoking in Germany (18 years) plus
5 years for the youngest smokers). Maximum age was set at
55 years to avoid age-related effects on BoBE. Smokers had to have
smoked 10–30 cigarettes with ISO tar yield 6–8 mg and blend typeFig. 1. Schematic otypical of the German market daily for at least 5 years (current
brand for >6 months) and to be willing both to switch to a novel
product and to smoke only supplied cigarettes during the study.
A urinary cotinine level of >100 ng/mL at screening was required.
Ex-smokers had to have not smoked for at least 5 years but previ-
ously regularly smoked 10–30 cigarettes per day for at least 5 years
and thus were aged 28–55 years. Never smokers had to be aged
28–55 years and not to have smoked more than 100 cigarettes
during their lifetime with none smoked in the previous 5 years. A
urinary cotinine level of <30 ng/mL at screening was required in
ex-smokers and never smokers.
Exceptions to the inclusion criteria were permitted at the
discretion of the investigators and sponsor, providing risks to
participants were not increased and the realisation of the scientiﬁc
objectives would not be hindered.
Universal exclusion criteria were: a clinically relevant health
condition or abnormal ﬁndings on physical examination or acute
illness requiring treatment within the previous 4 weeks; participa-
tion in a clinical trial within the previous 90 days; donation or loss
of P400 mL blood in the past 90 days; donation of plasma within
the previous 7 days; regular use of nicotine or tobacco products
other than ﬁltered cigarettes; any history of drug or alcohol abuse
within the previous 2 years; use of bronchodilators within the
previous 12 months; use of any medication that interferes with
the cyclo-oxygenase pathway or systemic medication (except
hormonal contraception or hormone-replacement therapy) within
the previous 14 days; use of any drugs or substances (except
tobacco) known to be strong inducers or inhibitors of cytochrome
P450 enzymes within the previous 28 days (Shepperd et al., 2013);
strenuous physical activity exceeding the normal levels within
7 days before screening or in-clinic evaluations; employment in
the tobacco, journalism, public relations, market research or
advertising industries; and a positive urine pregnancy test, use of
unreliable contraceptive methods or lactation in women of child-
bearing age. Women who became pregnant during the study were
withdrawn.
Smokers were excluded if they self-reported or were observed
to be non-inhalers or if they were planning to quit in the next
12 months. Non-smokers were excluded if they smoked at anyf RTP product.
NDay 1 first day of study, smokers start on supplied control cigarette
Clinical Confinement for 24h urine, 24h butt, blood sample collections, etc.
Ambulatory visits for cigarette re supply and compliance monitoring
Switch from control_v1 to RTP or control_v2 cigarette
7 8 9 10
1 2 3 Week number
Ex Smokers 30 Screening 1 2 3 4 5 6
8 9
23 2411 12 13 14
Never Smokers 30 Screening 1 2 3 4 5
19 20 21 2215 16 17 18
2219 20 2114 23 24
7mg Control A 35 Screening 1 2 3 4
1815 16 1710 11 12 136 7
2721 2219 2013 14 15 16
7mg Control B 35 Screening 1 2 3 4
25 2623 2417 189 10 11 125 6 7 8
2721 2219 2013 14 15 16
1 2 3 4
25 2623 2417 189 10 11 125 6 7 8
2721 2219 2013 14 15 16
7mg Test B 35 Screening 1 2 3 4
25 2623 2417 189 10 11 125 6 7 87mg Test A 35 Screening
13 14 15 169 10 11 125 6 7 8 25 2623 2417 18 2721 2219 20
Never Smokers 30
4 5 6Screening 1Ex Smokers 30
6
2 3 7
Screening 1 2 3
2420 21 22 2313 14 15 16 17 198
4 5
18
8 9 10 11 18
9 10
12 13
11 12
7 2420 21 22 231914 15 16 17
Fig. 2. Study design and scheduled events.
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second-hand smoke. Smokers were free to quit smoking at any
time, in which case they were withdrawn from the study.2.3. Study groups and visits
Smokers were assigned to receive the conventional product
(control group) or RTP (test group). Ex-smokers and never smok-
ers were enrolled to provide background levels of biomarkers.
Subjects were recruited and groups ﬁlled according to order of
screening, age, gender and availability at the start of the study,
and the demographics for all groups were matched as far as
possible. To ensure that enough participants were recruited to
all groups, subject availability was assured and groups were
well matched for age and gender, full randomisation was not
possible.
On days 1, 31, 62, 95, 124, 144 and 165 smokers visited the
clinic to collect supplies of cigarettes sufﬁcient for the next ambu-
latory period. To ensure the results and conclusions from this study
were realistic, smokers were required to smoke as naturally as pos-
sible and therefore were permitted to smoke ad libitum throughout
the study. Initial numbers of cigarettes supplied were based on
self-reported daily consumption at screening or during the previ-
ous ambulatory period, plus two packs (Fig. 2); subjects were not
told at screening that the supply would be based on these values.
Smokers also attended the study clinic for periods of clinical con-
ﬁnement, during which cigarettes were issued singly on request
after the ﬁlter from the previous cigarette had been returned.
This ensured complete collection of ﬁlters and accurate data on
cigarette consumption. If daily consumption increased during the
study, the supply was reviewed with the individual and adjusted
accordingly.
On day 1, all smokers received cork-tipped control cigarettes to
smoke in their usual manner. On the evening of day 12 smokers
entered the clinic for the ﬁrst period of clinical conﬁnement, when
24 h urine, blood and exhaled breath samples were collected for
analysis. Subjects also underwent physical examinations, pul-
monary function tests, electrocardiography and urine cotinine test-
ing with NicAlert™ (Palico, Rotkreuz, Switzerland) and completed
questionnaires on quality of life (to be reported elsewhere) and
smoking sensory experience. On the evening of Day 14 smokers
were switched to either the white-tipped control product or the
RTP, which they continued to smoke for the remainder of the
study. They attended the clinic for further 24–48 h periods of clin-
ical conﬁnement on days 46, 77, 109 and 182.Ex-smokers and never smokers attended the clinic for three
48 h periods of clinical conﬁnement, starting on days 2, 78 and
163. During these visits, 24 h urine and blood samples were col-
lected and they underwent physical examinations, pulmonary
function tests, electrocardiography and urine cotinine testing and
completed questionnaires on quality of life, diet and lifestyle.2.4. Determination of endpoints
2.4.1. Selection of biomarkers
The selection of BoE and BoED was based on conﬁrmed smoke
compositional changes in the RTP as compared with the control
product and the availability of validated biomarker methodologies.
All but one BoE were included in the primary objectives of this
study due to a reasonable expectation of change following a switch
to the RTP that was based on prior results. Urine mutagenicity was
deemed exploratory and, therefore, was included as a secondary
endpoint. BoBE selection was based on literature searches for pos-
sible associations between biomarkers and biological processes
related to exposure to smoke toxicants. Although this was not a
cessation study, the switching period of 6 months was based on
information from such studies, which indicated that measurable
changes in the levels of some BoBE can be seen within this
6 months. Thirty-four BoBE were identiﬁed as potentially useful
to measure. Some BoBE listed in the protocol (Shepperd et al.,
2013) were not included for methodological reasons: all levels of
interleukins 6 and 8 and tumour necrosis factor alpha were below
the limit of quantiﬁcation, and baseline levels of matrix metallo-
proteinases 1 and 9, tissue inhibitor of metalloproteinase 1 and
vascular endothelial growth factor were not obtained due to delays
in analysis that compromised the stability criteria. The most
promising four BoBE (F2-isoprostanes [8-iso-PGF2 type lll and
8-iso-PGF2 Type Vl], white blood cells and s-ICAM-1) were
assigned to the primary objective because of their reported associ-
ation with smoking-related disease and abilities to differentiate
between smoking status and demonstrate reversibility upon smok-
ing cessation (Lowe et al., 2009; Lowe et al., 2013). All other BoBE
were considered exploratory and were assigned to the secondary
objectives.2.4.2. Bioanalysis
Whilst resident in the clinic, 24 h urine samples were collected
from subjects for calculation of daily output of urinary biomarkers
(concentrations * total 24 h urine volume). At baseline and the end
of the study, two 24 h samples were collected to ensure a complete
Table 2
Characteristics of participants by study group.
Control
smokers
RTP
smokers
Ex-
smokers
Never-
smokers
Total
Enrolled (n) 67 (100%) 76
(100%)
61
(100%)
61 (100%) 265
(100%)
Completed
(n)
56 (83.6%) 58
(76.3%)
58
(95.1%)
57 (93.4%) 229
(86.4%)
Gender
Male 28 (50%) 27
(46.6%)
29 (50%) 29 (50.9%) 113
(49.3%)
Female 28 (50%) 31
(53.4%)
29 (50%) 28 (49.1%) 116
(50.7%)
Age
Mean (SD) 39.9 (8.75) 39.7
(9.31)
42.7
(7.75)
42.4 (7.25)
Median (min,
max)
43.0 (24,
54)
40.0 (23,
55)
44.0 (28,
55)
44.0 (28,
55)
Race
Caucasian 56 (100%) 58
(100%)
58
(100%)
55 (96.5%)
Non-
caucasian
0 0 0 2 (3.5%)
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measured 23 BoE and ﬁve BoBE in urine. The methods utilised
for measurement of BoE for aromatic amines and polycyclic aro-
matic hydrocarbons have been reported elsewhere (Riedel et al.,
2006; Ramsauer et al., 2011). Methods for BoE for nicotine and
metabolites, tobacco-speciﬁc nitrosamines, 1,3-butadiene, croton-
aldehyde, acrolein and acrylonitrile were adapted from published
methods (Roethig et al., 2007; Kavvadias et al., 2009; Urban
et al., 2003; Scherer et al., 2007; Ding et al., 2009). References to
all urinary BoBE methodologies can be found elsewhere (Haswell
et al., 2014). Urine mutagenicity was determined by use of reverse
mutation in YG1024, a histidine-requiring strain of Salmonella
typhimurium (Agurell and Stensman, 1992).
Of note, the nicotine BoE comprised nicotine plus ﬁve metabo-
lites, summed to provide ‘total nicotine equivalents’ (TNeq).
Similarly, for naphthalene, two metabolites (1- and 2-hydroxy
naphthalene) and for phenanthrene, ﬁve metabolites (1-, 2-, 3-,
4- and 9-hydroxy phenanthrene) were determined and summed
to provide ‘total OH naphthalene’ and ‘total OH phenanthrene’
respectively.
Blood samples were collected in blood-collection tubes for clin-
ical laboratory tests (safety data) (Shepperd et al., 2013b) and to
estimate concentrations of 29 additional BoBE (Haswell et al.,
2014) and two biomarkers of effective dose (BoED), which were
haemoglobin adducts of 2-cyanoethylvaline and 4-aminobiphenyl
(van Sittert, 1996; Lewalter and Gries, 2000).
Exhaled carbon monoxide levels were determined with an EC50
Micro III Smokerlyzer monitor (Bedfont Scientiﬁc, Maidstone, UK).
2.4.3. Cigarette consumption and mouth-level exposure (MLE)
Self-reported cigarette consumption was recorded at screening.
During ambulatory periods subjects recorded consumption as
cigarettes per day (CPD) in hand-held electronic diaries on smart-
phone devices (supplied and administered by CRF Health, Helsinki,
Finland). Subjects also answered questions about other products
smoked during ambulatory periods and an ‘honesty policy’ was
employed to ensure accurate reporting of non-compliance without
fear of exclusion from the study. On speciﬁed ambulatory days,
subjects collected all butts from cigarettes smoked and returned
these along with unsmoked cigarettes which was compared with
diary data to further assess compliance. During clinical conﬁne-
ment periods CPD was recorded by clinic staff on the basis of the
number of spent ﬁlters returned. Collected spent ﬁlters were sent
to the sponsor for part-ﬁlter analysis to assess MLE (Charles
et al., 2009). These values were compared with ISO
machine-smoking values.
2.4.4. Sensory questionnaire
A previously used questionnaire about sensory experience of
cigarette smoking (Shepperd et al., 2013b) was administered with
slight modiﬁcations. Smokers completed the questionnaire on a
tablet device (supplied and administered by CRF Health, Helsinki,
Finland) at baseline, immediately after the product switch and dur-
ing all conﬁnement visits. Magnitude and liking of each parameter
were scored for the following sensory features: acceptability, draw
effort, amount of smoke, satisfaction, irritation, nicotine impact,
taste amount and quality, mouth dryness and aftertaste.
2.4.5. Cigarette consumption questionnaire
Soon after switching, clinic staff reported widespread increases
in daily consumption which was reported to the ethics committee
and an independent Data Safety Monitoring Board (DSMB). The
DSMB recommended that the study continue, consumption moni-
toring during the study be increased, that subjects be administered
a questionnaire to ascertain the reasons for the consumption
increases, and that consumption be monitored for 8 weeksfollowing study completion. In addition the amount and intensity
of smoking cessation advice was increased. The ethics committee
agreed with these measures and all were implemented in the
study.
The questionnaire comprised two parts: a free-text response
section for all subjects who self-reported any changed consump-
tion, whether that was an increase or a decrease and a section in
which each subject was asked to rate the level of applicability on
a four-point scale for each of a series of speciﬁed factors that
possibly led to changed consumption.
2.5. Statistical analysis
Sample size calculations were based on estimates of expected
differences and standard deviations for F2-isoprostanes, white
blood cells and s-ICAM-1 reported in the literature for BoBE (16
studies) and on previously observed data for BoE (Shepperd
et al., 2013a). Calculations were made with MINITAB software
(version 15) and based on one-way ANOVA. A sample size of 50
yielded at least a 80% power to identify differences between study
groups for 75% of reported estimates. Literature searches for the
BoBE in the secondary endpoint were uninformative and, therefore,
sample size was assumed to be the same as for the primary objec-
tive. To allow for an anticipated attrition rate of 16% among smok-
ers and to make sure at least 50 participants in each smoking group
completed the study, we aimed to enrol 70 participants per smok-
ing group. Owing to lower expected attrition in the ex-smokers and
never-smoker groups, we aimed to recruit 60 to each.
Statistical analyses and data management were performed by
Celerion, Lincoln, NE, USA. The primary endpoint was change in
biomarker levels, and secondary endpoints included cigarette con-
sumption, MLE to nicotine and tar, and sensory experience. These
were examined by computation of group biomarker levels at base-
line, midpoints and at the end of the study. The data were checked
to ensure that model assumptions were satisﬁed. No transforma-
tions were required. For primary endpoints ANOVA was used to
identify differences both within and between groups and across
time points. To account for the possibility of changes in cigarette
consumption over time or because of the switch, ANCOVA was also
performed, with CPD as a covariate. For the secondary outcomes,
exploratory analysis and repeated-measures ANOVA was used to
identify differences over time within and between smoker groups
and products. The signiﬁcance level was set at 5%, and Tukey’s
HSD post hoc test was used to account for multiplicity.
Table 3
In-clinic cigarette consumption and nicotine and NFDPM mouth-level exposure (MLE).
Key: CPD = cigarettes per day; MLE = mouth-level exposure; NFDPM = nicotine-free dry particulate matter (‘tar’); EOS = End of study (day 183).
Fig. 3. Cigarette consumption (in-clinic data).
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3.1. Subjects
Characteristics of subjects are shown in Table 2. A total of 265
subjects entered the study: 143 smokers, 61 ex-smokers and 61
never smokers. Sixty-seven smokers were allocated to the control
group and 76 to the RTP group. Overall, 229 completed the study
(56 control smokers, 58 RTP smokers, 58 ex-smokers and 57 never
smokers). Of the 36 subjects who discontinued early, 10 withdrew
because of serious adverse effects resulting in hospitalisation
and/or surgery. The medically qualiﬁed principal investigator
considered that none of these SAEs were related to the study or
products. Two additional subjects were withdrawn because of
non-compliance, two due to protocol violations, one due to a pro-
gressive disease, one because of pregnancy and 20 for other rea-
sons that were not classiﬁed as adverse events. Age and gender
were well matched across all groups, taking into account the differ-
ent minimum age for smoker and non-smoker groups (Table 2).
3.2. Cigarette consumption
In clinic CPD increased by three (18.6%) or four (12.5%) cigar-
ettes per day overall in the control and test groups, respectively
after the switch (Table 3 and Fig. 3). Subsequently, clinical conﬁne-
ment CPD periods remained consistently in the range of 21–23cigarettes per day in both groups. The greatest change was seen
from baseline to the midpoint of the study after which CPD was
stable for the remainder of the study (Fig. 3). This increase in CPD must
be borne in mind when considering the biomarker data.
As described above, the increase in cigarette consumption was
unexpected and prompted an alert to the ethics committee and
set up of a DSMB, both of whom recommended study continuation
but an increase in consumption monitoring (including post study)
and implementation of a questionnaire to ascertain the reasons for
the change. Frequent monitoring using an electronic diary
generated multiple time points during ambulatory periods (in
addition to the consumption data acquired in the clinic). Data for
all time points are tabulated, and presented graphically, in
Supplementary data: Appendix 1. However, in keeping with the
biomarker data (see below) we focus on the clinical CPD data here
(Table 3 and Fig. 3).
Immediately after the study was completed, mean daily con-
sumption returned to pre-study levels, and by around 8 weeks of
post-study follow-up had dropped to 17 cigarettes per day in the
control group and 16 cigarettes per day in the test group
(Supplementary data: Appendix 1).
3.3. Biomarkers
Due to the large amount of data generated in this study, we pre-
sent only the baseline and end-of-study biomarker values. Full bio-
marker data are provided as Supplementary data: Appendix 2.
Here can be found the biomarker levels at all time points, and
the results of the statistical comparisons within and between
groups at all time points.
3.3.1. Biomarkers of exposure and effective dose
LevelsofBoEvaried little throughout thestudy inex-smokersand
never smokers (Supplementary data: Appendix 2) and therefore
only the means are shown here (Table 4). In smokers, levels of the
nicotine BoE TNeq were largely as expected from the combination
of the increased consumption over the course of the study
(Table4)and the10%difference innicotineyieldbetween thecontrol
and RTP product (Table 1), with increases of 10.8% in the control
group, and 25.5% in the RTP (Test) group by the end of the study.
Signiﬁcant increases from baseline were seen in the control
group for the BoEs NNK, NAB, NAT, 4-aminobiphenyl,
3-aminobiphenyl, 2-aminonapthalene, crotonaldehyde, acrolein,
acrylonitrile, ﬂuorene, naphthalene and carbon monoxide
(Table 4, Fig. 4), which were largely in keeping with the increase
in daily consumption. For one nitrosamine (NNN) and one aromatic
amine (o-toluidine), and one vapour phase constituent
Table 4
LS Means (95% Conﬁdence Intervals) and EOS vs baseline comparisons (p-values) for urinary biomarkers of exposure and effective dose.
Smoke constituent % Yield change
(RTP vs control)
BoE Control smokers Test smokers Ex-smokers Never-smokers
Baseline
(smoking
control v1)
EOS
(smoking
control v2)
% Change*
(EOS vs
baseline)
Baseline
(smoking
control v1)
EOS
(smoking
RTP)
% Change*
(EOS vs
baseline)
Mean Mean
Nicotine 10 TNeq (mg/24 h) 14.8
(13.4–16.3)
16.4
(14.9–17.9)
10.8 14.1
(12.7–15.5)
17.7
(16.2–19.1)
25.5 0.13 0.10
p = 0.004 (n = 56) p < 0.001 (n = 58)
NNK >62 NNAL (ng/24 h) 189.3
(170.7–208.0)
208.2
(189.6–226.8)
10.0 174.4
(155.9–192.8)
105.6
(87.1–124.1)
39.4 3.0 2.5
p = 0.003 (n = 56) p < 0.001 (n = 57)
NNN 86 NNN (ng/24 h) 10.8
(8.8–12.8)
10.7
(8.7–12.7)
0.9 7.9
(5.9–9.9)
2.8
(0.8–4.9)
64.6 0.5 0.6
p = 0.956 (n = 56) p < 0.001 (n = 55)
NAB 73 NAB (ng/24 h) 27.1
(24.0–30.2)
34.0
(30.8–37.1)
25.5 26.2
(23.2–29.3)
14.9
(11.8–18.0)
43.1 1.6 1.7
p = <0.001 (n = 56) p < 0.001 (n = 58)
NAT 55 NAT (ng/24 h) 167.9
(148.5–187.3)
209.3
(189.9–228.7)
24.7 159.0
(139.9–178.1)
114.6
(95.5–133.6)
27.9 2.6 3.3
p = <0.001 (n = 56) p < 0.001 (n = 58)
4-Amino biphenyl 50 4-Amino biphenyl (ng/
24 h)
17.6
(16.1–19.1)
21.0
(19.5–22.5)
19.3 16.8
(15.3–18.2)
14.0
(12.5–15.5)
16.7 2.6 2.4
p = <0.001 (n = 55) p < 0.001 (n = 58)
3-Amino biphenyl 44 3-Amino biphenyl (ng/
24 h)
7.2
(6.5–8.0)
7.9
(7.2–8.7)
9.7 7.2
(6.5–8.0)
5.0
(4.2–5.7)
30.6 0.4 0.6
p = 0.038 (n = 56) p < 0.001 (n = 58)
o-Toluidine 33 o-Toluidine (ng/24 h) 162.6
(150.3–174.9)
162.1
(149.8–174.4)
0.3 153.9
(141.8–166.0)
148.3
(136.2–160.3)
3.6 71.3 63.3
p = 0.938 (n = 56) p = 0.377 (n = 58)
2-Amino
Napthalene
44 2-Aminonapthalene
(ng/24 h)
26.6
(24.4–28.9)
29.7
(27.4–31.9)
11.6 25.6
(23.4–27.8)
23.0
(20.8–25.2)
10.2 1.0 0.4
p < 0.001 (n = 56) p = 0.002 (n = 58)
Croton-aldehyde 90 HMPMA (lg/24 h) 472.3
(425.9–518.8)
538.0
(491.6–584.5)
13.9 530.4
(484.7–576.1)
139.4
(93.8–185.1)
73.7 99.5 180.8
p = 0.008 (n = 56) p < 0.001 (n = 58)
Acrolein >94 3-HPMA (lg/24 h) 1355.1
(1215.5–1494.8)
1605.3
(1465.6–1744.9)
18.5 1314.7
(1177.3–1452.1)
869.4
(732.0–1006.8)
33.9 208.4 281.2
p < 0.001 (n = 56) p < 0.001 (n = 58)
1,3-Butadiene 87 MHBMA (ng/24 h) 4035.2
(3441.4–4628.9)
4191.4
(3597.7–4785.2)
3.9 4115.0
(3530.6–4699.3)
2860.2
(2275.9–3444.5)
30.5 121.4 144.7
p = 0.315 (n = 56) p < 0.001 (n = 58)
Acrylonitrile >95 CEMA (ng/24 h) 183.0
(164.5–201.6)
229.6
(211.1–248.2)
25.5 185.0
(166.7–203.2)
78.9
(60.6–97.1)
57.4 1.28 1.25
p < 0.001 (n = 56) p < 0.001 (n = 58)
Pyrene 10 1-OH Pyrene (ng/24 h) 393.2
(347.1–439.4)
296.2
(250.1–342.4)
24.7 389.9
(344.5–435.3)
274.8
(229.4–320.2)
29.5 145.0 116.3
p < 0.001 (n = 56) p < 0.001 (n = 58)
Fluorene 14 2-OH Fluorene (ng/
24 h)
3464.0
(2956.8–3971.2)
4711.5
(4204.3–5218.6)
36.0 2747.5
(2248.6–3246.4)
4977.2
(4478.3–5476.2)
81.1 899.5 874.4
p < 0.001 (n = 56) p < 0.001 (n = 58)
Naphthalene 79 Total OH Naphthalene
(ng/24 h)
23.3
(20.1–26.5)
33.3
(30.2–36.5)
42.9 23.2
(20.1–26.3)
35.9
(32.8–39.0)
54.7 3.7 3.5
p < 0.001 (n = 56) p < 0.001 (n = 58)
Phenanthrene 2 Total OH Phenanthrene
(ng/24 h)
831.2
(729.5–933.0)
844.3
(742.6–946.0)
1.6 748.4
(648.3–848.5)
892.1
(792.0–992.2)
19.2 462.8 496.1
p = 0.787 (n = 56) p = 0.003 (n = 58)
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the end of the study and the BoE for one smoke constituent
(pyrene) signiﬁcantly decreased in the control group. The levels
of BoEs in non-smokers were in keeping with published data
(Shepperd et al., 2013a; Gregg et al., 2013).
In the test group smoke yields for all of these toxicants were
reduced compared with the control product, and signiﬁcant reduc-
tions were also seen in the levels of all BoE, except o-toluidine,
which again showed no signiﬁcant change. The reductions in BoE
were generally less than those in smoke yields because daily
consumption increased, but reductions for some BoE were
substantial in both the particulate and vapour phase (NNN,
64.6%, crotonaldehyde, 73.7% and acrylonitrile, 57.4%). Of note is
the reduction in the level of NNAL, the biomarker for NNK, for
the test group. This urinary biomarker has a long half-life (typically
10–18 days (Goniewicz et al., 2009) and so the reduction in level
provides some indication of subject compliance during the ambu-
latory periods, despite the known consumption increase.
Smoke yields of PAHs varied greatly. For instance, reductions
were seen for pyrene (10%) and napthalene (79%) in RTP smoke
compared with control smoke, whereas little change or slight
increases were seen in smoke yields for others (phenanthrene 2%
and ﬂuorene 14%; Tables 1 and 4). Levels and changes in PAH BoE
were also variable. Pyrene BoE decreased signiﬁcantly in the both
smoking groups (Control -24.7%, Test –29.5%) whereas substantial
increases were seen in BoE levels for ﬂuorene (Control 36.0% and
Test 81.1%) and naphthalene (Control 42.9%, Test 54.7%) (Table 4).
The BoE for phenanthrene increased largely in line with CPD and
tar MLE results for the test group but did not change for the control
group smokers despite the similar CPD increase (Table 3, Table 4).
For the BoED, levels of urinary 4-aminobiphenyl and the hae-
moglobin adduct increased in controls by 19.3% and 26.5%, respec-
tively, whereas in RTP smokers a 16.7% decrease was seen in
urinary 4-aminobiphenyl with no signiﬁcant change in the haemo-
globin adduct (Table 4). Levels of urinary acrylonitrile biomarker
and 2-cyanoethlyvaline haemoglobin adduct increased in controls
(25.5% and 55.9%, respectively) but decreased in RTP smokers
(57.4% and 39.3%, respectively; Table 4). The haemoglobin
adducts have long body residence times (approximately 120 days
Scherer et al., 2014) and so this reduction provides some further
evidence of compliance for those subjects switched to the RTP.
Fig. 5 shows substantial separation between smokers and never
smokers in urine mutagenicity at the end of the study compared
with baseline. A signiﬁcant reduction in urine mutagenicity was
seen in the RTP group at the end of the study.
3.3.2. Biomarkers of biological effect
Among the BoBE in the primary objectives, levels of
8-iso-PGF2a type III were not signiﬁcantly different between base-
line and end of study (EOS) in both the control and RTP group,
whereas levels of 8-iso-PGF2a type VI showed a signiﬁcant
increase in the control group smokers (p = 0.003), but not in the
RTP group. Mean absolute levels of both 8-iso-PGF2a types III
and VI were higher than those in ex-smokers and never smokers
(Table 5, Fig. 6). With respect to white blood cell counts, there
was no signiﬁcant change between baseline and EOS for both the
control and RTP group, although higher absolute values were
observed in the RTP group at both time points compared to those
in the control group smokers (Table 5, Fig. 6). Finally, levels of
s-ICAM-1 signiﬁcantly increased in both the control and RTP
groups over the course of the study (p < 0.001), with higher abso-
lute levels observed in the RTP group at both baseline and EOS
compared to the control group smokers (Table 5, Fig. 6), which
suggest a potential product-related effect.
Most BoBE from the secondary objectives yielded little useful
data, with many showing no differences between smokers and
Fig. 4. Boxplots of selected biomarkers of exposure.
Group
Control group
Never smoker group
Test group
Mean Revertants vs. Urine Concentration
Baseline EOS
time_Point
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Fig. 5. Urine mutagenicity results.
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sions. To help identify potentially meaningful changes in the sec-
ondary BoBE we focused on those that satisﬁed the following
criteria (See Supplementary data: Appendix 2 for cross-sectional
comparisons): The BoBE showed a signiﬁcant difference between smokers of
the control product and never-smokers between no less than
two out of three time points (baseline, mid-point, end of
study).
Table 5
LS Means (95% conﬁdence intervals) and EOS vs baseline comparisons (p-values) for biomarkers of biological effect (BoBE).
BoBE Matrix Method Control smokers Test smokers Ex-smokers Never-smokers
Baseline
(smoking
control v1)
EOS
(smoking
control v2)
% Change
(EOS vs
baseline)
Baseline
(smoking
control v1)
EOS
(smoking
RTP)
% Change
(EOS vs
baseline)
Mean Mean
F2-isoprostane (8-iso-
PGF2 Type III) (ng/24 h)
Urine LC–MS/MS 244.6
(206.6–282.5)
287.4
(249.5–325.4)
17.5 252.9
(215.5–290.2)
261.0
(223.6–298.2)
3.2 152.0 143.8
p = 0.057 (n = 56) p = 0.716 (n = 58)
F2-isoprostane (8-iso-
PGF2 Type VI) (ng/24 h)
Urine LC–MS/MS 1483.0
(1339.6–1626.4)
1672.1
(1528.7–1815.5)
12.8 1551.2
(1410.1–1692.2)
1453.2
(1312.1–1594.3)
6.3 1396.1 1256.6
p = 0.003 (n = 56) p = 0.111 (n = 58)
White blood cells
(109 cells/L)
Blood Flow cytometry 7.0
(6.6–7.4)
7.3
(6.9–7.6)
4.3 7.7
(7.3–8.1)
7.7
(7.3–8.1)
0.0 5.7 5.5
p = 0.090 (n = 56) p = 0.946 (n = 58)
s-ICAM-1 (ug/L) Plasma ELISA 303.6
(265.4–341.8)
427.0
(388.9–465.2)
40.6 371.4
(333.9–409.0)
593.8
(556.3–631.3)
59.9 266.5 305.3
p < 0.001 (n = 56) p < 0.001 (n = 58)
8-OHdG (ng/24 h) Urine LC–MS/MS 4708.8
(4184.7–5232.9)
4905.5
(4381.4–5429.6)
4.2 5117.3
(4601.6–5633.0)
4266.9
(3751.2–4782.7)
16.6 4882.5 4609.4
p = 0.300 (n = 56) p < 0.001 (n = 58)
cis-thymidine glycol (ng/24 h) Urine LC–MS/MS 2638.8 (2378.1–2899.5) 2245.5
(1984.8–2506.2)
14.9 2653.9
(2397.4–2910.4)
2316.1
(2059.6–2572.6)
12.7 2308.7 2217.8
p < 0.001 (n = 56) p = 0.001 (n = 58)
11-dehydroxy
thromboxane B2 (ng/24h)
Urine LC–MS/MS 807.5
(711.2–903.9)
895.7
(798.7–992.6)
10.9 840.4
(748.2–932.6)
679.4
(587.1–771.6)
19.2 709.3 609.6
p = 0.056 (n = 51) p < 0.001 (n = 57)
Neutrophil count
(109 cells/L)
Blood Flow cytometry 3.83
(3.54–4.13)
3.92
(3.62–4.21)
2.3 4.33
(4.04–4.62)
4.23
(3.93–4.52)
2.3 3.02 2.91
p = 0.516 (n = 56) p = 0.406 (n = 58)
Monocyte count
(109 cells/L)
Blood Flow cytometry 0.56
(0.52–0.60)
0.62
(0.58–0.66)
10.7 0.64
(0.60–0.69)
0.62
(0.58–0.66)
3.1 0.52 0.47
p < 0.001 (n = 56) p = 0.185 (n = 58)
SOD activity to Hb ratio
(U/umol)
Erythrocytes Enzyme Activity 3.60
(3.31–3.89)
3.55
3.25–3.84)
1.4 4.83
(4.55–5.12)
4.20
(3.92–4.49)
13.0 3.98 3.70
p = 0.791 (n = 56) p = 0.002 (n = 58)
GPx activity to Hb ratio
(nm/min/um)
Erythrocytes Enzyme Activity 326.5
(306.0–347.5)
297.3
(276.8–318.4)
8.9 327.8
(307.8–348.6)
287.6
(267.5–308.4)
12.3 352.3 343.1
p < 0.001 (n = 56) p < 0.001 (n = 58)
Glutathione reductase
activity to Hb ratio (nm/min/um)
Erythrocytes Enzyme Activity 24.8
(20.9–28.8)
16.2
(12.2–20.1)
34.7 36.2
(32.3–40.1)
7.3
(3.4–11.2)
79.8 18.1 21.8
p = 0.002 (n = 56) p < 0.001 (n = 58)
Catalase activity to Hb
ratio (nm/min/um)
Erythrocytes ELISA 2263.8
(2108.5–2419.1)
898.4
(743.1–1053.7)
60.3 1142.6
(989.9–1295.2)
1243.0
(1090.3–1395.7)
8.8 1240.6 1051.1
p < 0.001 (n = 56) p = 0.337 (n = 58)
Malondialdehyde to Hb
ratio (nmol/mmol)
Erythrocytes LC–MS/MS 137.5
(104.0–170.9)
216.9
(183.5–250.3)
57.7 102.4
(69.5–135.2)
277.5
(244.6–310.3)
171.0 155.0 161.0
p < 0.001 (n = 56) p < 0.001 (n = 58)
Ascorbic acid (umol/L) Plasma LC–MS/MS 54.0
(49.5–58.5)
54.0
(49.5–58.5)
0 55.3
(50.9–59.8)
48.6
(44.1–53.0)
12.1 60.4 60.7
p = 0.982 (n = 56) p < 0.001 (n = 58)
Dehydroascorbic acid
(umol/L)
Plasma LC–MS/MS 24.2
(22.7–25.8)
23.0
(21.4–24.5)
5.0 24.6
(23.1–26.1)
22.5
(21.0–24.0)
8.5 25.04 26.29
p = 0.225 (n = 56) p = 0.047 (n = 58)
Total antioxidant
capacity (mmol/L)
Serum Colorimetric 1.51
(1.49–1.54)
1.59
(1.56–1.62)
5.3 1.54
(1.51–1.56)
1.64
(1.61–1.66)
6.5 1.54 1.57
p < 0.001 (n = 56) p < 0.001 (n = 58)
(continued on next page)
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Table 5 (continued)
BoBE Matrix Method Control smokers Test smokers Ex-smokers Never-smokers
Baseline
(smoking
control v1)
EOS
(smoking
control v2)
% Change
(EOS vs
baseline)
Baseline
(smoking
control v1)
EOS
(smoking
RTP)
% Change
(EOS vs
baseline)
Mean Mean
hsCRP (males) (mg/L) Serum Turbidity 1.07
(0.26–1.87)
1.84
(1.03–2.65)
72.0 1.48
(0.63–2.32)
1.16
(0.32–2.00)
21.6 0.92 1.59
p = 0.168 (n = 28) p = 0.587 (n = 26)
Total cholesterol
(mg/dL)
Serum Enzyme Activity 188.0
(177.5–198.5)
203.8
(193.3–214.3)
8.4 198.1
(187.8–208.5)
203.5
(193.2–213.8)
2.7 198.0 194.7
p < 0.001 (n = 56) p = 0.170 (n = 58)
LDL (mg/dL) Serum Derived by
Friedewald’s equation
115.3
(106.4–124.2)
125.2
(116.3–134.1)
8.6 124.8
(116.0–133.6)
127.4
(118.6–136.2)
2.1 119.6 115.2
p = 0.002 (n = 56) p = 0.393 (n = 58)
HDL (mg/dL) Serum Enzyme Activity 48.3
(44.7–51.9)
51.3
(47.7–54.8)
6.2 48.7
(45.2–52.2)
52.6
(49.1–56.1)
8.0 56.3 57.9
p = 0.017 (n = 55) p = 0.002 (n = 58)
Triglycerides (mg/dL) Serum Enzyme Activity 117.1
(101.6–132.7)
124.6
(109.0–140.1)
6.4 122.6
(107.2–137.9)
117.4
(102.1–132.7)
4.2 114.4 107.5
p = 0.151 (n = 56) p = 0.309 (n = 58)
Fibrinogen (mg/dL) Plasma Coagulation 289.4
(277.0–301.8)
300.0
(287.6–312.3)
3.7 295.6
(283.5–307.8)
291.7
(279.5–303.8)
1.3 273.1 288.1
p = 0.090 (n = 56) p = 0.516 (n = 58)
MCP-1 (ng/L) Plasma Multiplexed ELISA 120.5
(111.9–129.2)
105.6
(97.0–114.3)
12.4 142.3
(133.7–150.8)
149.2
(140.7–157.7)
4.8 106.7 103.3
p < 0.001 (n = 56) p = 0.106 (n = 58)
Neutrophil elastase
(ng/mL)
Plasma ELISA 32.2
(29.9–34.5)
11.8
(9.5–14.2)
63.4 25.4
(23.1–27.7)
10.9
(8.6–13.2)
57.1 13.0 12.4
p < 0.001 (n = 56) p < 0.001 (n = 58)
LTB4 (ng/L) Plasma ELISA 14.2
(7.4–21.1)
10.0
(3.2–16.9)
29.6 14.0
(7.3–20.7)
8.7
(2.0–15.4)
37.9 23.6 16.9
p = 0.346 (n = 56) p = 0.223 (n = 58)
oxLDL (U/L) Plasma ELISA 76.8
(71.4–82.1)
77.1
(71.8–82.5)
0.4 72.1
(66.8–77.4)
69.4
(64.1–74.6)
3.7 63.2 59.5
p = 0.885 (n = 56) p = 0.284 (n = 58)
Key: LS = least square; s-ICAM-1 = soluble intercellular adhesion molecule; 8-OHdG = 8-hydroxydeoxyguanosine; SOD = superoxide dismutase; GPx = glutathione peroxidase; hsCRP = high sensitivity C-reactive protein; LDL = low
density lipoprotein; HDL = high density lipoprotein; MCP-1 = monocyte chemotactic protein 1; LTB4 = leukotriene B4; oxLDL = oxidised LDL.
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Fig. 6. Boxplots of selected biomarkers of biological effect.
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never-smokers between no less than two out of three time
points (baseline, mid-point, end of study).
Thus, these biomarkers are differentially useful or show longi-
tudinal stability. The biomarkers that satisﬁed these criteria were
11-dehydrothromboxane B2, monocyte count, monocyte chemo-
tactic protein-1 (MCP-1) and HDL cholesterol (Table 5).
Levels of urinary 11-dehydrothromboxane B2 were signiﬁcantly
lower in the RTP group at the EOS compared to baseline (p < 0.001),
whereas the smoking control group showed no signiﬁcant differ-
ence between baseline and EOS, which suggest a product-related
effect following the switch to the RTP. Mean absolute levels of
11-dehydrothromboxane B2 in the RTP group at EOS were compa-
rable to the pooled levels in the ex-smoker group, but were higher
than those in the never smoker group. Monocyte counts increased
signiﬁcantly between baseline and EOS in the control group
(p < 0.001), but not in the RTP group. Mean absolute monocyte
counts were higher in both smoking groups compared to former
and never-smokers. Plasma MCP-1 levels were signiﬁcantly lower
in the smoking control group (p < 0.001) and showed no signiﬁcant
difference in the RTP group, between baseline and EOS. Mean
absolute levels of MCP-1 were higher in both smoking groups
compared with those in non-smokers. Levels of HDL cholesterol
increased signiﬁcantly in both the control group (p = 0.017) and
the RTP group (p = 0.002) from baseline to EOS, and approached
the mean absolute levels observed in non-smokers by EOS.
Unlike BoE, the levels of some BoBE in non-smokers did change
over time and, therefore, pooled mean values are presented for ref-
erence (Table 5).3.4. Mouth level exposure (MLE)
MLE changed in the control group only in line with the increase
in CPD. Under ISO machine smoking conditions the RTP delivered
10% more nicotine and 10% less tar than the control product
(Table 1). In the study, however, an increase of 55% was seen for
MLE to nicotine in the RTP group (Table 3), obviously due to
increased intensity of smoking as well as increases in CPD.
However, this increase was not fully reﬂected in the biomarker
data.
Biomarker and MLE endpoints were also assessed using
ANCOVA. CPD was consistently found to be a signiﬁcant covariate
in the statistical models evaluating the BoE and MLE endpoints, but
generally was not a signiﬁcant covariate in the statistical models
evaluating the BoBE. In most cases, similar high-level interpreta-
tions (group * period interaction, group and period effects) were
found when CPD was included in or excluded from the statistical
model.3.5. Sensory questionnaire
The sensory questionnaire data are summarised in Fig. 7. For
the control group, most scores did not change throughout the
study period except for overall acceptability, appearance and rod
length acceptability which were signiﬁcantly lower than at base-
line, and irritation which was higher immediately after the switch.
Post-switch control group scores did not change for the remainder
of the study. In the RTP group, scores for all attributes (except for
nicotine impact (‘kick’) sensation, mouth/throat irritation, mouth
Fig. 7. Mean sensory questionnaire scores for both products by study group.
Fig. 8. Scores for pre-speciﬁed possible reasons for increased daily cigarette consumption. Questions are translated from the original German.
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negative direction immediately after the switch. However, sensory
perception of the RTP product improved during the study in the
direction of baseline.3.6. Cigarette consumption questionnaire
Changes in mean CPD were reported by 54 subjects in the con-
trol group and 43 in the test group. In the free-text part of the
questionnaire, 26 (49%) subjects in the control group cited the
availability of free cigarettes as being an important factor in the
increase. Twenty-two (40%) described the post-switch control
cigarettes as smoking faster, seeming ‘‘lighter’’, shorter or contain-
ing less tobacco. In the test group, 33 (76%) subjects reported that
an important factor for increased consumption was the shorter and
slimmer format of the product, and 17 (39%) said that reduced sen-
sory experience was a factor.
Among the scored statements, response to the statement ‘‘The
study cigarettes don’t last as long as my usual brand’’ received
the highest score in both groups (Fig. 8). In the control group, the
other highest-scoring reasons for smoking more cigarettes were
‘‘I sometimes smoke one study cigarette soon after another’’,
‘‘The cigarettes are free of charge’’, ‘‘The study cigarettes are very
satisfying’’, ‘‘The study cigarettes taste good’’, and ‘‘Being on the
study’’. In the test group the next highest-scoring reasons were ‘‘I
sometimes smoke one study cigarette soon after another’’, ‘‘Study
cigarettes may be less harmful than my usual brand’’, ‘‘I was in
company of friends’’ and ‘‘The cigarettes were free of charge’’
(Fig. 8).4. Discussion
The primary objective of this study was to estimate changes in
levels of BoE and BoBE in smokers switched from a conventional
cigarette to an RTP. Previous work demonstrated that the switch-
ing of smokers from a control to an RTP cigarette for 4 weeks
resulted in signiﬁcant reductions in exposure to toxicants (as
determined by BoE levels) that were largely in line with changes
in smoke composition (Shepperd et al., 2013a). Increased CPD
meant that we anticipated that reductions in BoE might not be as
great as seen in the short-term study (Shepperd et al., 2013a)
and, therefore, that potential changes in BoBE might be partially
negated. The switch to the RTP nonetheless resulted in signiﬁcant
reductions in many BoE levels. The end-of-study levels for the four
tobacco-speciﬁc nitrosamines, three of the four aromatic amines
and all the vapour-phase toxicants (crotonaldehyde, acrolein
1,3-butadiene and acrylonitrile) were signiﬁcantly reduced in the
RTP group compared with levels at baseline. Reductions in these
BoE were on average around 70% of those in the 6-week study,
but were sustained throughout the 6-month study period. In the
control group BoE levels for these toxicants unexpectedly
increased by up to 25.5% over the duration of the study, probably
because of increased CPD. These increases, however, allowed us
to investigate whether decreases and increases in certain BoE are
associated with any changes in BoBE.
With the exception of 1-OH pyrene, the BoE for the PAHs gener-
ally increased in the control and RTP groups. The RTP
machine-smoking ISO naphthalene yields were 79% lower than
those for the control product. However, after smokers switched
to the RTP, levels of the naphthalene BoE increased by approxi-
mately 54.7%. A somewhat similar effect was also seen in the
6-week study, where large reductions in naphthalene smoke yield
in the RTP resulted in no signiﬁcant change to the related BoE
(Shepperd et al., 2013a). The discrepancy between the large reduc-
tion in naphthalene smoke yield but no change or increase of itsBoE in both studies cannot be explained at present, although the
inﬂuence of dietary sources of PAH’s cannot be ruled out.
Similarly, the RTP ﬂuorene smoke yields showed a modest increase
compared with control (14%), whereas the BoE level increased sub-
stantially (81%). In this case, no similar effect was seen previously
and, apart from dietary inﬂuences, we have no explanation for this
anomaly (Shepperd et al., 2013a). It could be possible to extend the
MLE method to include PAHs and this additional evidence may
provide some explanation for these ﬁndings.
Urine mutagenicity in smokers has previously been shown to
differ signiﬁcantly from that in non-smokers (Kado et al., 1983),
and our results conﬁrm this. Urine mutagenicity in the RTP group
was signiﬁcantly reduced compared with that in the control group
and is likely to be in keeping with the reduction in exposure to
mutagenic species in smoke. Indeed, the bacterial mutagenicity
of particulate matter from the RTP cigarettes have been shown to
be signiﬁcantly lower than the control cigarette (Crooks et al.,
2015).
For the BoED, moderate correlations were found between the
haemoglobin adducts and their parent compound in the smoke.
In 2008 Gyorffy and colleagues (Gyorffy et al., 2008) proposed a
model to describe the biomarker continuum for genotoxicants that
included biomarkers of internal dose (typically urinary biomark-
ers), effective dose (adducts with macromolecules), and early bio-
logical effect. In this study, we found a signiﬁcant reduction in
levels of 2-cyanoethylvaline haemoglobin adducts between base-
line and EOS in the test group which corresponds to the reduction
in the level of the urinary biomarker for acrylonitrile, CEMA.
However, no signiﬁcant change in 4-ABP haemoglobin adducts
was seen in the test group at the end of study. This may have been
because the toxicant reductions in the smoke were relatively
modest, and were likely off-set by the increase in consumption.
A comprehensive analysis of the correlation between haemoglobin
adducts for acrylonitrile and 4-aminobiphenyl and their corre-
sponding urinary metabolite has been reported elsewhere
(Scherer et al., 2014).
The BoBE measured are implicated in key processes that con-
tribute to the development and progression of smoking-related
diseases, including oxidative stress, inﬂammation and DNA
damage. For instance, elevated levels of F2-isoprostanes have been
associated with smoking-related diseases via oxidative-stress-
mediated mechanisms (Morrow, 2005; Rahman, 2005). Levels of
urinary and plasma isoprostane are higher in smokers than in
non-smokers (Lowe et al., 2013), but decrease signiﬁcantly after
smoking cessation (Flores et al., 2004; Morrow et al., 1995;
Chehne et al., 2002; Oguogho et al., 2000). Despite the lack of
change in the levels of 8-iso-PGF2a type III following a switch to
the RTP, levels of this BoBE between smokers and non-smokers
continued to be signiﬁcant throughout the study (p < 0.001, See
Supplementary data: Appendix 2). With respect to 8-iso-PGF2a
type VI, the data show elevated levels in the control smoking group
and no change in the RTP group at the end of study. However, there
is signiﬁcant heterogeneity in the data to the point where
8-iso-PGF2a type VI was unable to discriminate between current
and never-smokers at baseline (Supplementary data: Appendix
2). Hence, data for 8-iso-PGF2a type VI are not robust enough to
draw any clear conclusions.
Elevations in white blood cell counts have been associated with
smoking and smoking-related disease (Frohlich et al., 2003; Lao
et al., 2009), and decreases have been reported following smoking
cessation (Frohlich et al., 2003; Blann et al., 1997; Hammet et al.,
2007). In this study, there was no signiﬁcant difference over time
in either the smoking control or RTP group. Given that a signiﬁcant
difference between smokers and non-smokers’ WBC count was
maintained for each time point over the course of the study (see
Supplementary data: Appendix 2), this gives a degree of conﬁdence
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no product-related effect. The monocyte counts followed a very
similar pattern to WBC, which indicates that the test product had
no speciﬁc effects on this BoBE.
11-dehydrothromboxane B2 is a urinary metabolite of the
potent platelet agonist and vasoconstrictor, thromboxane A2.
Raised concentrations of the urinary metabolite are associated
with platelet activation and smoking status (Wennmalm et al.,
1991; Lowe et al., 2009; Nowark et al., 1987; Frost-Pineda et al.,
2011) and decrease signiﬁcantly following smoking cessation
(Rangemark et al., 1993; Saareks et al., 2001) or a switch to an elec-
trically heated tobacco product (Roethig et al., 2008). Throughout
the study period, levels of 11-dehydrothromboxane B2 in the con-
trol group remained signiﬁcantly higher than in the never-smoker
group and became a signiﬁcantly different from values in the
ex-smoker group at the study midpoint and EOS time points (see
Supplementary data: Appendix 2). This ﬁnding could potentially
be due to the increase in cigarette consumption during the study
in the smoking control group. Interestingly, despite the increase
in cigarette consumption also reported in the RTP group, levels of
11-dehydrothromboxane B2 signiﬁcantly decreased over the
course of the study. These data suggest that the chemical yield
reductions in the RTP product may have been partly responsible
for the reductions in 11-dehydrothromboxane B2 levels, and could
contribute to elevations in 11-dehydrothromboxane B2 generally
observed in smokers of conventional cigarettes. Levels of the
tobacco-speciﬁc nitrosamine NNK were shown to be signiﬁcantly
reduced in the RTP from machine-smoked chemistry data
(Table 1), and data from this study showed signiﬁcantly lower
levels of urinary NNAL (a urinary metabolite of NNK) in the RTP
group than in the smoking control group. Huang et al. (2011)
recently reported that NNK increased the synthesis of thrombox-
ane A2 in human lung cancer cells, which was associated with
prolonged cellular survival. Hence, the relative reductions in the
RTP NNK smoke yields and corresponding reductions in urinary
NNAL could explain why levels of 11-dehydrothromboxane B2
were lower in the Test group than the control group at the end
of the study. If this association were proven, then thromboxane
A2-mediated cell survival in lung cells could be a possible mecha-
nism by which NNK induces its reported carcinogenic effects.
Although this is an interesting hypothesis, caution should be
exercised when relating cause to effect by association alone, and
further studies are needed to fully explore this hypothesis to
understand any potential causal relationship and its implications
for respiratory disease.
Recruitment of inﬂammatory cells from the vascular system is
an essential part of the damage-repair process in endothelial dys-
function and tissue injury, and elevations in levels of s-ICAM-1 and
MCP-1 are implicated in the development of atherosclerosis
(Piemonti et al., 2009; Deo et al., 2004; Gross et al., 2012;
Kusano et al., 2004). With respect to plasma MCP-1 levels, a signif-
icant reduction was observed in the control group, whereas in the
RTP group values did not differ signiﬁcantly between baseline and
EOS. Clear conclusions are difﬁcult to draw from these data due to
the apparent variability in the smoking groups. A signiﬁcant differ-
ence between smokers and non-smokers was maintained until the
mid-point of the study, however at the EOS time-point, MCP-1
levels sharply increased in the RTP group, whereas levels sharply
decreased to that of non-smoker levels in the control group (see
Supplementary data: Appendix 2). This ﬁnding suggests the switch
to the RTP had no clear favourable effects in terms of MCP-1 levels.
With respect to plasma s-ICAM-1, initial baseline comparisons of
smokers and non-smokers showed no signiﬁcant difference in
levels of s-ICAM-1 (Haswell et al., 2014). However, following the
product switch, levels of s-ICAM-1 in the control and RTP groups
were consistently higher than non-smokers (p < 0.001, seeSupplementary data; Appendix 2). Absolute levels of s-ICAM-1 in
the RTP group at EOS were substantially higher than those in the
control group. These data suggest that the RTP had a potentially
adverse effect on the test population. The biological rationale for
such an increase is not clear. Given the lack of discrimination
between smokers and non-smokers for s-ICAM-1 at baseline (in
contrast to published literature) and the apparently higher
s-ICAM-1 levels in ex-smokers than in never smokers also at the
end of the study (see Supplementary data: Appendix 2), it is possi-
ble that methodological variance might be responsible for the dif-
ferences, however this hypothesis is difﬁcult to conﬁrm. Assuming
that the method is sound, it is clear that the RTP had no beneﬁcial
effects in terms of s-ICAM-1 levels.
Finally, modulation of the serum lipid proﬁle in smokers is asso-
ciated with development of cardiovascular disease. HDL choles-
terol levels are signiﬁcantly lower in smokers compared with
non-smokers (Chelland Campbell et al., 2008) and increase in peo-
ple who have quit smoking (Gross et al., 2012; Ohsawa et al., 2005;
Hata and Nakajima, 2000) or switched to an electronically heated
tobacco product (Roethig et al., 2008). Accordingly, we found con-
sistently lower concentrations of HDL cholesterol in smokers than
in non-smokers. The signiﬁcant increase in HDL levels seen in both
groups of smokers during the study may have been due to reasons
other than smoking, such as dietary inﬂuences.
For BoBE, switching to the RTP only demonstrated one
potentially beneﬁcial effect with decreased levels of
11-dehydrothromboxane B2, and one potentially adverse effect
with increased s-ICAM-1 levels This general lack of response in
BoBE levels to a reduction in toxicant exposure was highlighted
in a similar study by Sarkar et al. who reported no signiﬁcant
changes in selected cardiovascular disease-related BoBE following
a forced switch from a conventional cigarette to a cigarette con-
taining activated carbon in the ﬁlter (Sarkar et al., 2008). There
are various possible explanations for the BoBE ﬁndings. The study
period of 6 months might not have been long enough to detect any
meaningful changes, despite literature reports indicating changes
in BoBE levels following smoking cessation occurred within the
time-frame of this study. Additionally, few or none of the toxicants
reduced in the RTP might affect the mechanistic pathways linked
to the measured BoBE, and reductions in other toxicants could
prove to be of greater importance for these speciﬁc end-points. A
further possibility is that samples for measurement of BoBE were
taken during clinical conﬁnement. Despite increased CPD during
these periods, subjects reported even greater daily cigarette con-
sumption during ambulatory periods (Supplementary data:
Appendix 1) and, therefore, the potential reductions in exposure
in the RTP group might be overestimated and increases in exposure
in the control group underestimated. Some important drivers of
disease are respiratory irritants and greater reductions in these
toxicants than achieved might be needed to affect BoBE levels.
Perhaps of greater concern is that the RTP group might have expe-
rienced an adverse effect related to increased s-ICAM-1 levels,
despite experiencing reductions in various BoE, including several
currently under consideration for regulatory monitoring and possi-
bly mandated lowering. Finally, although the study was sufﬁciently
powered to detect changes in the primary objective BoBE over
time, based upon smoking cessation data, it may not have been
sufﬁciently powered to detect changes in subjects who continue
to smoke, albeit switching to a product with reduced machine
smoked toxicant yields. Indeed, the inclusion of a cessation arm
in this study would have clariﬁed the true utility of the BoBE
included. If no changes in BoBE level had been seen following com-
plete cessation, then none would be seen following the switch to
the RTP. This limitation should be addressed in future work.
Our data do not challenge the basic premise that
smoking-related diseases are caused by sustained repeated
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cessation of smoking. They do however, suggest that selective tox-
icant lowering/removal from combustible tobacco products may
have relatively little effect on health risks, or may have small pos-
itive or negative effects. Our data suggest that more research is
needed on the potential for modifying health risks through
changes in toxicant levels in cigarette smoke.
In the previous 6-week study, apart from a slight uplift in CPD
in some smoking groups on the last day of that study, consumption
changed little. In this 6-month study signiﬁcant increases in cigar-
ette consumption were seen in both smoker groups. The greatest
increases were seen during the ambulatory periods of the study,
whereas during days of clinical conﬁnement when clinic staff
allocated cigarettes and collected butts to record consumption,
increases were modest (never more than on average three or four
more cigarettes than at screening). We cannot be absolutely
certain how much consumption increased overall owing to
self-reporting and the possibility of stockpiling or sharing cigar-
ettes with others during ambulatory periods, but the numbers of
cigarette butts collected at these times generally corroborated con-
sumption levels recorded in the diaries. No smoker increased
beyond a limit of 60 cigarettes per day and the study continued
despite the observed increase in CPD.
In the test group, the possibility that the RTPs were less harmful
than conventional cigarettes was given as a key reason given for
smoking more, but this reason did not score highly in the control
group. The subjects were informed of the purpose of the study
before volunteering to participate, received information about tox-
icants in smoke and learned that the research was being conducted
to study the potential health effects of reducing toxicants in smoke.
Subjects in the test groupmight have connected the unusually long
ﬁlter with potential risk reduction, but masking of this fundamen-
tal change in the product was not possible. Further study is
required of how such product risk information is best communi-
cated to potential consumers and of how product appearance inﬂu-
ences consumption patterns. Such work would support the FDA
requirement that information on the levels of harmful and poten-
tially harmful constituents in tobacco smoke for cigarette brands
sold in the USA be clearly communicated to the public. Research
has shown, however, that smokers have little understanding of
such toxicants despite knowing that smoking is extremely harmful
(Hammond et al., 2006).
The increased CPD was similar in the control and RTP groups.
Subjects in both groups scored the reason ‘‘The cigarettes are free
of charge’’ highly in the questionnaire. We believed when we
designed the study that we would need to provide all the cigarettes
at no cost and to supply, within reason, as many products as the
subjects required to ensure that the ambulatory aspect of the study
would be as naturalistic as possible as well as to optimise compli-
ance with smoking only study cigarettes. Restriction of study cigar-
ettes to the amount typically smoked at screening might have
lessened the risk of increased consumption and should be explored
in future studies. Alternatively, we could increase the stipend for
volunteering but require that some of money be used to purchase
study cigarettes. As the RTPs were sensorially different from the
smokers’ regular brands, however, use of the money to supplement
with and/or return to conventional cigarettes would be difﬁcult to
control.
5. Conclusions
Our aim was to test the hypothesis that the reduced exposure to
cigarette smoke toxicants obtained through switching to an RTP
from a conventional cigarette would reduce levels of potential
biomarkers of smoking-related disease, as assessed through mea-
surement of BoBE. An unexpected increase in daily cigaretteconsumption, apparently driven substantially by the provision of
free cigarettes, made assessment difﬁcult because the reductions
in exposure from the RTP were generally less than in our previous
study (Shepperd et al., 2013b), although they were still quite large
for some toxicants. Additionally, the increased consumption led to
the control group having greater exposure to toxicants during the
study than normal. Nevertheless, these unexpected exposure
patterns had no major effect on the BoBEs that distinguish smokers
from ex-smokers and never smokers. Greater reductions in RTP
toxicant yields and/or a longer study period might show more
substantial effects, but more research would be needed to demon-
strate this. Additionally, we believe our ﬁndings provide useful
insights into study design for potential MRTPs and indicate areas
of research to investigate effective modes of communication to
the public of information regarding tobacco smoke toxicants and
MRTPs.
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